Upgrade to FINVIZ Elite to get real-time quotes, intraday charts, and advanced charting tools. Subscribe to Elite

ARWR

Arrowhead Pharmaceuticals Inc

Jan 07 • 04:00PM ET

65.69

-5.12 -7.23 %

Healthcare • Biotechnology • USA • NASD

Jan 06, 10:01 AMInterim Phase 1/2a obesity trial data revealing doubled weight loss versus tirzepatide alone propelled 18% intraday surge.

Peers: ALNY IONS SRPT NBIX DTIL VRTX RGNX CRSP EDIT NTLA

| Held by: IJR IWM VTI VB XBI VBK SPSM IWO IJT VXF

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-0.07	Insider Own	7.28%	Shs Outstand	135.70M	Perf Week	-2.32%
Market Cap	8.92B	Forward P/E	-	EPS next Y	-4.50	Insider Trans	-5.46%	Shs Float	125.92M	Perf Month	6.92%
Enterprise Value	8.77B	PEG	-	EPS next Q	0.11	Inst Own	81.17%	Short Float	8.13%	Perf Quarter	79.78%
Income	-1.63M	P/S	10.76	EPS this Y	-33013.08%	Inst Trans	5.72%	Short Ratio	4.26	Perf Half Y	247.93%
Sales	829.45M	P/B	19.13	EPS next Y	-35.90%	ROA	-0.13%	Short Interest	10.23M	Perf YTD	-1.05%
Book/sh	3.43	P/C	9.70	EPS next 5Y	-	ROE	-0.50%	52W High	76.76 -14.42%	Perf Year	231.94%
Cash/sh	6.77	P/FCF	56.86	EPS past 3/5Y	80.60% 57.10%	ROIC	-0.14%	52W Low	9.57 586.42%	Perf 3Y	61.96%
Dividend Est.	-	EV/EBITDA	71.75	Sales past 3/5Y	50.52% 56.63%	Gross Margin	97.12%	Volatility	7.51% 6.04%	Perf 5Y	-15.16%
Dividend TTM	-	EV/Sales	10.58	EPS Y/Y TTM	99.12%	Oper. Margin	11.86%	ATR (14)	4.65	Perf 10Y	959.52%
Dividend Ex-Date	-	Quick Ratio	4.86	Sales Y/Y TTM	23258.15%	Profit Margin	-0.20%	RSI (14)	53.26	Recom	1.85
Dividend Gr. 3/5Y	- -	Current Ratio	4.86	EPS Q/Q	87.24%	SMA20	-3.52%	Beta	1.22	Target Price	75.70
Payout	-	Debt/Eq	1.57	Sales Q/Q	-	SMA50	19.83%	Rel Volume	2.98	Prev Close	70.81
Employees	711	LT Debt/Eq	1.47	Earnings	Nov 25 AMC	SMA200	127.07%	Avg Volume	2.40M	Price	65.69
IPO	Dec 16, 1993	Option/Short	Yes / Yes	EPS/Sales Surpr.	1.43% 46.29%	Trades		Volume	7,157,439	Change	-7.23%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-05-24	Initiated	Goldman	Neutral	$31
Dec-04-23	Initiated	BofA Securities	Buy	$29
Sep-19-23	Initiated	Citigroup	Neutral	$33
Jul-21-23	Initiated	TD Cowen	Outperform
May-12-23	Downgrade	SVB Securities	Outperform → Market Perform	$40
Apr-26-23	Initiated	SMBC Nikko	Outperform	$80
Apr-12-23	Upgrade	SVB Securities	Market Perform → Outperform	$21 → $35
Mar-21-23	Initiated	Bernstein	Mkt Perform	$27
Sep-09-22	Initiated	Morgan Stanley	Equal-Weight	$41
May-11-22	Upgrade	Robert W. Baird	Neutral → Outperform	$71 → $60
Jan-19-22	Resumed	Goldman	Buy	$90 → $85
Aug-06-21	Reiterated	Chardan Capital Markets	Buy	$97 → $94
Jun-04-21	Resumed	Robert W. Baird	Neutral	$85
Feb-05-21	Reiterated	H.C. Wainwright	Buy	$90 → $95
Dec-21-20	Downgrade	Robert W. Baird	Outperform → Neutral	$75
Dec-16-20	Initiated	UBS	Buy	$95
Nov-19-20	Initiated	Citigroup	Buy	$90
May-13-20	Initiated	RBC Capital Mkts	Outperform	$62
May-08-20	Upgrade	Oppenheimer	Perform → Outperform	$58
Apr-15-20	Upgrade	Cantor Fitzgerald	Neutral → Overweight	$55 → $60

Show Previous Ratings

Today 07:30AM	Arrowhead Pharmaceuticals Announces NMPA Approval of REDEMPLO (plozasiran) for Familial Chylomicronemia Syndrome (FCS) in China (Business Wire) -7.23%
Jan-06-26 06:14PM	Arrowhead Pharmaceuticals Announces Proposed Offerings of Convertible Senior Notes and Common Stock (Business Wire) +10.85%
11:26AM	Zepbound Boost Gets a Lift From Arrowhead's Drug. The Question Is Whether Patients Will Pay. (Barrons.com)
07:35AM	Arrowhead Says Its Gene Silencer Doubled Zepbound's Weight Loss (Investor's Business Daily)
07:30AM	Arrowhead Pharmaceuticals Announces Interim Clinical Data on RNAi-based Obesity Candidates Showing Weight Loss in Obese Patients with Diabetes and Improved Measures of Body Composition (Business Wire)
07:30AM	Loading…
Jan-05-26 07:30AM	Arrowhead Pharmaceuticals Announces Health Canada Approval of REDEMPLO (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS) (Business Wire) -5.77%
Dec-23-25 07:30AM	Arrowhead Pharmaceuticals to Participate in Upcoming January 2026 Events (Business Wire)
Dec-15-25 04:30PM	Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) (Business Wire) -5.54%
Dec-12-25 08:00AM	Arrowhead price target raised to $80 from $52 at RBC Capital (TipRanks)
Dec-08-25 07:30AM	Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-MAPT for the Treatment of Alzheimer's Disease and Other Tauopathies (Business Wire) +11.65%
Dec-02-25 07:30AM	Arrowhead Pharmaceuticals Receives FDA Breakthrough Therapy Designation for Plozasiran in Severe Hypertriglyceridemia (Business Wire)
Dec-01-25 04:00PM	Arrowhead Pharmaceuticals to Participate in Upcoming December 2025 Conferences (Business Wire) +6.74%
Nov-27-25 06:51AM	Arrowhead (ARWR) Hits 3-Year High on Strong Earnings, FDA Approval (Insider Monkey)
Nov-26-25 07:16PM	Why Arrowhead Pharmaceuticals Stock Surged by Over 23% Today (Motley Fool) +23.34% -8.68%
05:47AM	Novartis cuts hundreds of jobs; Novos dual-acting diabetes drug heading to Phase 3 (BioPharma Dive)
12:00AM	Loading…
12:00AM	Arrowhead Pharmaceuticals Inc (ARWR) Q4 2025 Earnings Call Highlights: FDA Approval and ... (GuruFocus.com)
Nov-25-25 04:00PM	Arrowhead Pharmaceuticals Reports 2025 Fiscal Year-End Results (Business Wire) +5.72%
01:08PM	Sarepta's Stock Rises on Positive Updates on DM1 Therapy (Zacks)
Nov-24-25 07:30AM	Arrowhead Pharmaceuticals Earns $200 Million Milestone Payment from Sarepta Therapeutics (Business Wire) +9.42%
Nov-19-25 12:52PM	Arrowhead nets first commercial win as siRNA drug garners FDA approval (Pharmaceutical Technology)
Nov-18-25 11:52AM	Arrowhead Pharmaceuticals Announces FDA Approval of REDEMPLO (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS) (Business Wire)
07:39AM	RNAi biotech Arrowhead wins first FDA approval (BioPharma Dive)
Nov-06-25 04:30PM	Arrowhead Pharmaceuticals to Webcast Fiscal 2025 Year-End Results (Business Wire)
Nov-04-25 01:46PM	SRPT Q3 Earnings Miss Estimates, Stock Dips on DMD Study Failure (Zacks)
07:30AM	Arrowhead Pharmaceuticals to Participate in Upcoming November 2025 Conferences (Business Wire)
Oct-28-25 04:30PM	Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) (Business Wire)
Oct-21-25 07:30AM	Arrowhead Pharmaceuticals Announces Closing of Global License and Collaboration Agreement with Novartis (Business Wire)
Sep-11-25 07:30AM	Arrowhead Pharmaceuticals Files Complaint for Declaratory Judgment Against Ionis Pharmaceuticals (Business Wire)
Sep-10-25 11:06AM	NVS to Acquire TRML, Add Phase III Cardiovascular Drug to Pipeline (Zacks)
07:30AM	Arrowhead Pharmaceuticals Requests Regulatory Clearance to Initiate Phase 1/2a Study of ARO-MAPT for the Treatment of Alzheimer's Disease and Other Tauopathies (Business Wire)
12:59AM	Loading…
12:59AM	H.C. Wainwright Reiterated a Buy on Arrowhead Pharmaceuticals (ARWR) (Insider Monkey)
Sep-05-25 07:44AM	Why Shares in Arrowhead Pharmaceuticals Surged on News of a Novartis Deal (Motley Fool)
Sep-03-25 04:14PM	Arrowhead Lands Billion-Dollar Biotech Deal: Stock Soars Double-Digits (GuruFocus.com) +8.26%
09:42AM	NVS Inks a Licensing Deal With Arrowhead for siRNA Therapy (Zacks)
Sep-02-25 09:53AM	Arrowhead Pharma Jumps After Inking A Deal Worth Up To $2.2 Billion (Investor's Business Daily) +16.57%
08:03AM	Novartis thinks Arrowhead brain drug can succeed where others couldnt (BioPharma Dive)
07:30AM	Arrowhead Pharmaceuticals and Novartis Enter into a Global License and Collaboration Agreement (Business Wire)
Aug-27-25 07:30AM	Arrowhead Pharmaceuticals to Participate in Upcoming September 2025 Conferences (Business Wire)
Aug-21-25 09:33AM	Sarepta Gets Breathing Room in $700 Million Debt Restructure (Bloomberg)
Aug-20-25 04:41PM	Goodbye, Mag 7! These 3 Buy-Rated Small-Cap Stocks Are Starting to Outperform. (Barchart)
Aug-18-25 12:31PM	Arrowhead (ARWR) Climbs 24.9% on $100-Million Licensing Revenue (Insider Monkey)
Aug-15-25 10:42AM	Stock Market Today: Dow approaches fresh record despite disappointing economic data drop (TheStreet) +9.21%
Aug-14-25 04:18PM	Sarepta Sells Arrowhead Stake To Stretch Its Cash Runway; And One Stock Dives (Investor's Business Daily) -6.05%
11:41AM	Sarepta Sells Biotech Stake to Raise Cash as Elevidys Troubles Hit Home (Barrons.com)
11:24AM	Sarepta Sells Arrowhead Stake to Fund Milestone Payment (Zacks)
07:29AM	Sarepta sells Arrowhead shares as partnership, debt payments loom (BioPharma Dive)
Aug-13-25 04:12PM	Sarepta Therapeutics Announces Advancement of siRNA Collaboration and Sale of Arrowhead Equity Investment (Business Wire) +12.30%
04:10PM	Arrowhead Pharmaceuticals Redeems Approximately $50 Million of Arrowhead Stock and Will Receive Approximately $50 Million in Cash in Satisfaction of Milestone from Sarepta Therapeutics (Business Wire)
Aug-07-25 04:10PM	Arrowhead Research: Fiscal Q3 Earnings Snapshot (Associated Press Finance)
04:01PM	Arrowhead Pharmaceuticals Reports Fiscal 2025 Third Quarter Results (Business Wire)
09:29AM	Sarepta Soars on Q2 Earnings & Sales Beat, Resumes Elevidys Deliveries (Zacks)
Aug-04-25 11:07AM	Sarepta to Report Q2 Earnings: What's in Store for the Stock? (Zacks)
Aug-01-25 06:30AM	Arrowhead Subsidiary Visirna Sells Rights to Hypertriglyceridemia Candidate Plozasiran in Greater China to Sanofi (Business Wire)
Jul-31-25 11:58AM	Arrowhead Pharmaceuticals, Inc. (ARWR) Secures $100M Milestone from Sarepta in RNAi Breakthrough Deal (Insider Monkey)
Jul-30-25 08:30AM	Madrigal buys into GLP-1 from CSPC; Apellis wins expanded drug approval (BioPharma Dive)
Jul-28-25 04:55PM	Stocks Hold at Record, Dollar Jumps on Trade Hopes: Markets Wrap (Bloomberg)
07:30AM	Arrowhead Pharmaceuticals Earns $100 Million Milestone from Sarepta Therapeutics (Business Wire)
Jul-24-25 04:30PM	Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) (Business Wire)
Jul-23-25 08:00AM	Arrowhead Pharmaceuticals Issues Statement on the Status of its Ongoing Agreement with Sarepta Therapeutics (Business Wire) +6.42%
Jul-22-25 03:40PM	Arrowhead Pharma (ARWR) Shares Dragged by Sarepta Concerns (Insider Monkey)
Jul-21-25 04:01PM	Arrowhead Pharmaceuticals to Webcast Fiscal 2025 Third Quarter Results (Business Wire) -12.23%
Jul-17-25 10:58AM	SRPT Stock Soars on Unveiling New Restructuring Plan, Pipeline Pivots (Zacks)
Jul-16-25 04:01PM	Sarepta Therapeutics Announces Strategic Restructuring and Pipeline Prioritization Plan to Maintain Long-term, Sustainable Growth and Provides Update on ELEVIDYS Label (Business Wire)
Jul-09-25 05:32AM	Arrowhead doses first patient in Phase III trial of zodasiran for HoFH treatment (Clinical Trials Arena) +7.64%
Jul-08-25 07:30AM	Arrowhead Pharmaceuticals Initiates Phase 3 YOSEMITE Study of Investigational Zodasiran for the Treatment of Homozygous Familial Hypercholesterolemia (Business Wire)
Jul-01-25 05:32AM	Chronic Hepatitis B Market Analysis and Forecast, 2025-2035 \| Diagnostic Advances, Innovative Therapies, and Rising Awareness Bolster Growth (GlobeNewswire)
Jun-23-25 07:30AM	Arrowhead Pharmaceuticals Completes Enrollment in SHASTA-3, SHASTA-4, and MUIR-3 Phase 3 Studies of Plozasiran (Business Wire)
Jun-05-25 05:10AM	Jim Cramer on Arrowhead Pharmaceuticals (ARWR): "It Doesn't Make Any Money" (Insider Monkey)
Jun-03-25 08:28PM	Lightning Round: Buy Dover right now, says Jim Cramer (CNBC TV)
05:37AM	Arrowhead commences dosing in Phase I/IIa obesity treatment trial (Clinical Trials Arena)
Jun-02-25 07:30AM	Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-ALK7 for the Treatment of Obesity (Business Wire)
May-29-25 07:30AM	Arrowhead Pharmaceuticals to Participate in June 2025 Investor Conferences (Business Wire) +8.10%
May-13-25 03:07AM	Arrowhead Pharmaceuticals Inc (ARWR) Q2 2025 Earnings Call Highlights: Strong Financials and ... (GuruFocus.com) +9.38%
May-12-25 04:10PM	Arrowhead Research: Fiscal Q2 Earnings Snapshot (Associated Press Finance) +7.21%
04:01PM	Arrowhead Pharmaceuticals Reports Fiscal 2025 Second Quarter Results (Business Wire)
May-07-25 02:14PM	Sarepta: ELEVIDYS DMD Treatment Setback Brings Downgrade To Hold Rating (Seeking Alpha)
12:14PM	Sarepta Therapeutics: Lowered Elevidys Guidance Warrant Ratings Downgrade (Seeking Alpha)
08:31AM	SRPT Q1 Earnings Miss, Sales Beat, Stock Slides 21% on '25 View Cut (Zacks)
07:30AM	Arrowhead Pharmaceuticals to Participate in May 2025 Investor Conferences (Business Wire)
May-05-25 07:49AM	Why Arrowhead Pharmaceuticals, Inc. (ARWR) is Among the Best Small Cap Stocks to Buy with the Biggest Upside Potential (Insider Monkey)
Apr-30-25 04:01PM	Arrowhead Pharmaceuticals to Webcast Fiscal 2025 Second Quarter Results (Business Wire)
Apr-26-25 08:50AM	Novo Nordisk: Examining Tariff And Pricing Risks (Seeking Alpha)
Apr-19-25 05:30AM	ClearBridge Small Cap Strategy Q1 2025 Commentary (Seeking Alpha)
Apr-15-25 04:00PM	Arrowhead Pharmaceuticals Appoints Daniel Apel as Chief Financial Officer (Business Wire) -11.81%
Apr-04-25 04:30PM	Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) (Business Wire) -11.44%
Mar-28-25 09:00AM	RNA Biotechs: Current State And Outlook (Seeking Alpha)
Mar-24-25 08:25AM	How to Play SRPT Stock After Patient Death Post DMD Therapy Infusion (Zacks)
Mar-21-25 05:56PM	Arrowhead Pharmaceuticals Is Finally Arriving (SeekingAlpha)
Mar-10-25 02:02PM	Arrowhead Pharmaceuticals Stock Falls After Early-Stage Data From RNA-Based Therapeutic For Kidney Diseases (Benzinga) -10.37%
07:30AM	Arrowhead Pharmaceuticals Announces Topline Results from Part 2 of Phase 1/2 Study of ARO-C3 in Patients with IgA Nephropathy (Business Wire)
Mar-06-25 08:45AM	Arrowhead Pharmaceuticals Showcases Two Clinical-Stage RNAi-Based Candidates to Treat Obesity and Metabolic Diseases (Business Wire)
Feb-28-25 09:00AM	Arrowhead Pharmaceuticals Launches on Rare Disease Day New Patient-Centric Resources for Those Affected by Familial Chylomicronemia Syndrome (FCS) (Business Wire)
Feb-25-25 07:30AM	Arrowhead Pharmaceuticals Presents Preclinical Data on ARO-ALK7 for Treatment of Obesity (Business Wire)
Feb-20-25 12:15PM	Arrowhead Pharmaceuticals (ARWR): Among the Most Oversold Healthcare Stocks to Buy Now (Insider Monkey)
Feb-11-25 10:10AM	Q1 2025 Arrowhead Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents) -5.17%
02:06AM	Arrowhead Pharmaceuticals Inc (ARWR) Q1 2025 Earnings Call Highlights: Strategic Collaborations ... (GuruFocus.com)
Feb-10-25 04:08PM	Arrowhead Research: Fiscal Q1 Earnings Snapshot (Associated Press Finance)
04:01PM	Arrowhead Pharmaceuticals Reports Fiscal 2025 First Quarter Results (Business Wire)
08:30AM	Arrowhead Pharmaceuticals Announces Closing of Global License and Collaboration Agreement with Sarepta Therapeutics (Business Wire)
Jan-22-25 05:54PM	Guidewire Software Set to Join S&P MidCap 400; Arrowhead Pharmaceuticals to Join S&P SmallCap 600 (PR Newswire) +9.23%

Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development of medicines that treat intractable diseases by silencing the genes that cause them. The firms preclinical stage drug candidates include ARO-ANG3, ARO-AAT, ARO-APOC3, ARO-HIF2, ARO-HSD, ARO-Lung2, ARO-COV, and ARO-ENaC. The company was founded by Robert Bruce Stewart in 1989 and is headquartered in Pasadena, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
O'Brien Patrick	COO	Jan 05 '26	Sale	63.11	49,493	3,123,349	474,908	Jan 05 09:50 PM
Hamilton James C	Chief Medical Officer	Jan 05 '26	Sale	63.11	40,164	2,534,661	171,958	Jan 05 09:41 PM
Anzalone Christopher Richard	Chief Executive Officer	Jan 02 '26	Sale	66.10	13,187	871,703	3,792,739	Jan 05 09:39 PM
James Hamilton	Officer	Jan 05 '26	Proposed Sale	63.09	39,728	2,506,627		Jan 05 04:59 PM
Patrick O'Brien	Officer	Jan 05 '26	Proposed Sale	63.10	49,493	3,123,172		Jan 05 04:58 PM
Christopher Anzalone	Officer	Jan 02 '26	Proposed Sale	66.10	13,187	871,668		Jan 02 04:04 PM
Anzalone Christopher Richard	Chief Executive Officer	Dec 29 '25	Option Exercise	6.15	51,726	318,115	3,857,652	Dec 30 05:46 PM
Anzalone Christopher Richard	Chief Executive Officer	Dec 29 '25	Sale	69.13	51,726	3,575,575	3,805,926	Dec 30 05:46 PM
Ferrari Mauro	Director	Dec 26 '25	Sale	70.00	7,530	527,100	69,053	Dec 30 05:46 PM
Christopher Anzalone	Officer	Dec 29 '25	Proposed Sale	69.13	51,726	3,575,575		Dec 29 04:23 PM
Mauro Ferrari	Director	Dec 26 '25	Proposed Sale	70.00	7,530	527,070		Dec 29 04:03 PM
Waddill William D.	Director	Dec 19 '25	Sale	67.65	8,367	566,038	56,563	Dec 23 06:01 PM
Vakiener Victoria	Director	Dec 19 '25	Sale	67.68	10,040	679,491	35,723	Dec 23 06:01 PM
Anzalone Christopher Richard	Chief Executive Officer	Dec 19 '25	Sale	67.66	13,445	909,683	3,818,512	Dec 23 06:01 PM
Anzalone Christopher Richard	Chief Executive Officer	Dec 22 '25	Sale	68.44	12,586	861,340	3,805,926	Dec 23 06:01 PM
OLUKOTUN ADEOYE Y	Director	Dec 19 '25	Sale	67.66	10,000	676,623	33,600	Dec 23 06:01 PM
Christopher Anzalone	Officer	Dec 22 '25	Proposed Sale	68.43	12,586	861,319		Dec 22 04:00 PM
Anzalone Christopher Richard	Chief Executive Officer	Dec 17 '25	Sale	64.04	85,000	5,443,462	3,831,957	Dec 19 06:56 PM
Christopher Anzalone	Officer	Dec 19 '25	Proposed Sale	67.66	13,445	909,632		Dec 19 04:08 PM
William Waddill	Director	Dec 19 '25	Proposed Sale	67.65	8,367	566,001		Dec 19 04:07 PM
Adeoye Olukotun	Director	Dec 19 '25	Proposed Sale	67.66	10,000	676,589		Dec 19 04:07 PM
Victoria Vakiener	Director	Dec 19 '25	Proposed Sale	67.68	10,040	679,464		Dec 19 04:06 PM
Christopher Anzalone	Officer	Dec 17 '25	Proposed Sale	64.04	85,000	5,443,253		Dec 17 05:11 PM
Christopher Anzalone	Officer	Dec 16 '25	Proposed Sale	62.58	54,298	3,398,142		Dec 16 04:47 PM
Anzalone Christopher Richard	Chief Executive Officer	Dec 15 '25	Sale	68.85	130,000	8,950,615	3,971,255	Dec 16 01:14 PM
Anzalone Christopher Richard	Chief Executive Officer	Dec 16 '25	Sale	62.58	54,298	3,398,187	3,916,957	Dec 16 01:14 PM
Christopher Anzalone	Officer	Dec 15 '25	Proposed Sale	68.85	130,000	8,950,580		Dec 15 04:50 PM
PERRY MICHAEL S	Director	Dec 05 '25	Sale	61.03	16,250	991,738	115,240	Dec 09 06:04 PM
Michael Perry	Director	Dec 05 '25	Proposed Sale	60.99	16,250	991,129		Dec 05 04:00 PM
Ferrari Mauro	Director	Nov 28 '25	Sale	56.39	8,750	493,412	68,764	Dec 01 06:10 PM
Mauro Ferrari	Director	Nov 28 '25	Proposed Sale	56.35	8,750	493,062		Nov 28 01:19 PM
Hamilton James C	Chief Medical Officer	Oct 01 '25	Sale	35.00	20,000	700,000	212,122	Oct 03 06:15 PM
James Hamilton	Officer	Oct 01 '25	Proposed Sale	35.00	20,000	700,015		Oct 01 03:44 PM
Hamilton James C	Chief Medical Officer	Sep 12 '25	Sale	30.00	15,000	450,000	232,122	Sep 16 06:06 PM
Hamilton James C	Officer	Sep 12 '25	Proposed Sale	30.00	15,000	449,970		Sep 12 04:33 PM
Hamilton James C	Chief Medical Officer	Sep 02 '25	Sale	25.00	15,000	375,000	247,122	Sep 04 05:37 PM
Hamilton James C	Officer	Sep 02 '25	Proposed Sale	25.00	15,000	374,970		Sep 02 05:12 PM
Hamilton James C	Chief Medical Officer	Aug 15 '25	Sale	20.00	9,389	187,780	262,122	Aug 15 05:59 PM
Hamilton James C	Chief Medical Officer	Aug 13 '25	Sale	20.00	611	12,220	271,511	Aug 15 05:59 PM
Hamilton James C	Officer	Aug 15 '25	Proposed Sale	20.00	9,389	187,750		Aug 15 03:42 PM
Sarepta Therapeutics, Inc.	Shareholder	Aug 13 '25	Proposed Sale	19.99	9,265,312	185,213,587		Aug 13 08:55 PM
Hamilton James C	Officer	Aug 13 '25	Proposed Sale	19.95	611	12,190		Aug 13 05:57 PM
Myszkowski Kenneth Allen	Officer	Jul 10 '25	Proposed Sale	19.04	40,000	761,709		Jul 10 04:30 PM
Anzalone Christopher Richard	Chief Executive Officer	Apr 11 '25	Sale	11.49	50,800	583,692	3,921,255	Apr 11 06:20 PM
Anzalone Christopher Richard	Chief Executive Officer	Apr 10 '25	Sale	10.87	50,000	543,500	3,972,055	Apr 11 06:20 PM
Anzalone Christopher Richard	Chief Executive Officer	Apr 09 '25	Sale	10.07	40,322	406,145	4,022,055	Apr 11 06:20 PM
Anzalone Christopher Richard	Officer	Apr 11 '25	Proposed Sale	11.49	50,800	583,751		Apr 11 04:29 PM
Anzalone Christopher Richard	Officer	Apr 10 '25	Proposed Sale	10.86	50,000	543,215		Apr 10 04:35 PM
Anzalone Christopher Richard	Officer	Apr 09 '25	Proposed Sale	10.07	40,322	406,057		Apr 09 04:44 PM
Anzalone Christopher Richard	Chief Executive Officer	Mar 13 '25	Sale	15.07	51,425	774,975	4,062,377	Mar 17 05:45 PM
Anzalone Christopher Richard	Officer	Mar 13 '25	Proposed Sale	15.07	51,425	774,785		Mar 13 04:46 PM
Anzalone Christopher Richard	Chief Executive Officer	Mar 03 '25	Option Exercise	7.75	166,667	1,291,669	3,940,469	Mar 05 06:32 PM
Anzalone Christopher Richard	Chief Executive Officer	Mar 04 '25	Option Exercise	7.75	133,333	1,033,331	4,073,802	Mar 05 06:32 PM
Anzalone Christopher Richard	Chief Executive Officer	Mar 03 '25	Sale	18.03	166,667	3,005,006	3,907,135	Mar 05 06:32 PM
Anzalone Christopher Richard	Chief Executive Officer	Mar 04 '25	Sale	17.02	133,333	2,269,328	3,773,802	Mar 05 06:32 PM
Anzalone Christopher Richard	Officer	Mar 04 '25	Proposed Sale	17.02	133,333	2,268,742		Mar 04 05:48 PM
Anzalone Christopher Richard	Officer	Mar 03 '25	Proposed Sale	18.03	166,667	3,004,203		Mar 03 05:09 PM
OLUKOTUN ADEOYE Y	Director	Jan 23 '25	Sale	21.00	959	20,139	35,781	Jan 27 07:22 PM
OLUKOTUN ADEOYE Y	Director	Jan 23 '25	Proposed Sale	20.97	959	20,108		Jan 23 04:43 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ARWR

Arrowhead Pharmaceuticals Inc

Upgrade your FINVIZ experience